• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs

cafead

Administrator
Staff member
  • cafead   Jul 25, 2024 at 11:32: AM
via On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter adjusted EPS of $2.65, down 8.9% year over year, beating the consensus of $2.57.

Net revenues reached $14.46 billion, up 4.3%, beating the consensus of $14.03 billion. Sales were up 5.6% on an operational basis.

article source
 

<